APGE (Apogee Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by APGE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | Tomas Kiselak | Director | M | — | — |
| 2026-08-07 | Carl Dambkowski | Chief Medical Officer | MIXED | — | — |
| 2026-08-07 | Carl Dambkowski | Chief Medical Officer | MIXED | — | — |
| 2026-07-24 | Jane Henderson | Chief Financial Officer | G | — | — |
| 2026-07-16 | Carl Dambkowski | Chief Medical Officer | G | — | — |
| 2026-07-10 | MICHAEL THOMAS HENDERSON | Chief Executive Officer | MIXED | — | — |
| 2026-07-02 | Carl Dambkowski | Chief Medical Officer | MIXED | — | — |
| 2026-06-24 | Carl Dambkowski | Chief Medical Officer | Sell | — | — |
| 2026-06-24 | MICHAEL THOMAS HENDERSON | Chief Executive Officer | Sell | — | — |
| 2026-06-12 | MICHAEL THOMAS HENDERSON | Chief Executive Officer | Sell | — | — |
| 2026-06-11 | Lisa Bollinger | Director | A | — | — |
| 2026-06-11 | Tomas Kiselak | Director | A | — | — |
| 2026-06-11 | Mark C. McKenna | Director | A | — | — |
| 2026-06-11 | Nimish P Shah | Director | A | — | — |
| 2026-06-11 | Jennifer A. Fox | Director | A | — | — |
| 2026-06-11 | WILLIAM A JR JONES | Director | A | — | — |
| 2026-06-05 | Carl Dambkowski | Chief Medical Officer | MIXED | — | — |
| 2026-05-15 | MICHAEL THOMAS HENDERSON | Chief Executive Officer | Sell | — | — |
| 2026-05-08 | Carl Dambkowski | Chief Medical Officer | MIXED | — | — |
| 2026-05-04 | Jane Henderson | Chief Financial Officer | Sell | — | — |
| 2026-04-20 | MICHAEL THOMAS HENDERSON | Chief Executive Officer | M | — | — |
| 2026-04-17 | Jane Henderson | Chief Financial Officer | Sell | — | — |
| 2026-04-10 | MICHAEL THOMAS HENDERSON | Chief Executive Officer | Sell | — | — |
| 2026-04-03 | Carl Dambkowski | Chief Medical Officer | MIXED | — | — |
| 2026-04-03 | Jane Henderson | Chief Financial Officer | Sell | — | — |
| 2026-03-27 | Jane Henderson | Chief Financial Officer | Sell | — | — |
| 2026-03-13 | MICHAEL THOMAS HENDERSON | Chief Executive Officer | Sell | — | — |
| 2026-03-06 | Carl Dambkowski | Chief Medical Officer | MIXED | — | — |
| 2026-03-04 | Jane Henderson | Chief Financial Officer | Sell | — | — |
| 2026-02-13 | MICHAEL THOMAS HENDERSON | Chief Executive Officer | Sell | — | — |
| 2026-02-04 | Jane Henderson | Chief Financial Officer | Sell | — | — |
| 2026-02-04 | Carl Dambkowski | Chief Medical Officer | MIXED | — | — |
| 2026-01-22 | Tomas Kiselak | Director | Sell | — | — |
| 2026-01-16 | MICHAEL THOMAS HENDERSON | Chief Executive Officer | Sell | — | — |
| 2026-01-09 | Carl Dambkowski | Chief Medical Officer | MIXED | — | — |
| 2026-01-06 | Carl Dambkowski | Chief Medical Officer | A | — | — |
| 2026-01-06 | MICHAEL THOMAS HENDERSON | Chief Executive Officer | A | — | — |
| 2026-01-06 | Jane Henderson | Chief Financial Officer | Sell | — | — |
| 2025-12-23 | Jane Henderson | Chief Financial Officer | Sell | — | — |
| 2025-12-12 | MICHAEL THOMAS HENDERSON | Chief Executive Officer | Sell | — | — |
| 2025-12-05 | Jane Henderson | Chief Financial Officer | Sell | — | — |
| 2025-12-05 | MICHAEL THOMAS HENDERSON | Chief Executive Officer | Sell | — | — |
| 2025-12-05 | Carl Dambkowski | Chief Medical Officer | Sell | — | — |
| 2025-11-28 | Jane Henderson | Chief Financial Officer | Sell | — | — |
| 2025-11-14 | Jane Henderson | Chief Financial Officer | Sell | — | — |
| 2025-11-13 | MICHAEL THOMAS HENDERSON | Chief Executive Officer | Sell | — | — |
| 2025-11-13 | Jane Henderson | Chief Financial Officer | Sell | — | — |
| 2025-11-07 | Carl Dambkowski | Chief Medical Officer | MIXED | — | — |
| 2025-10-15 | Nimish P Shah | Director | Buy | — | — |
| 2025-10-03 | Carl Dambkowski | Chief Medical Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 1,750,000 | — |
| — | Chief Executive Officer | 920,941 | — |
| — | Chief Medical Officer | 168,498 | — |
| — | Chief Financial Officer | 158,371 | — |
| — | Director | 51,166 | — |
| — | Director | 20,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the APGE quote page; the site-wide leaderboard is on the insider transactions hub.